As the U.S. markets opened on Friday, investors are weighing the implications of the upcoming termination of the Medicare Part D premium subsidy program. The Centers for Medicare & Medicaid Services (CMS) has confirmed that the temporary premium reduction policy, which has been in effect for 2026, will be discontinued following the year. This development is set to reshape the competitive landscape for standalone prescription drug plans (PDPs) and could trigger significant member churn.
Centene Corporation (NYSE: CNC) emerges as the insurer most vulnerable to this policy shift. Approximately 90% of Centene's prescription drug plan members are enrolled in standalone Part D plans, a concentration that far exceeds its peers. This high dependency on standalone plans means that any changes in premium subsidies could directly impact member retention and plan attractiveness.
The 2026 demonstration program, which had an estimated cost of $3.6 billion, provided participating plans with a $10 per month reduction in base premiums. The termination of this program is not merely a loss of revenue; it introduces uncertainties around plan value, customer loyalty, and beneficiary choices. For investors, these factors are critical to watch as the market adjusts to the new pricing environment.
In contrast, CVS Health (NYSE: CVS) occupies a middle ground, with a more balanced mix of standalone PDP and Medicare Advantage (MA-PD) members. Humana (NYSE: HUM) and UnitedHealth Group (NYSE: UNH) hold larger Medicare Advantage drug portfolios, which provides them with greater internal retention capabilities if members shift between channels. This structural advantage could buffer them against the adverse effects of the subsidy phaseout.
Enrollment and Premium Dynamics
According to data from the Kaiser Family Foundation (KFF), the breakdown of 2026 Part D enrollment highlights Centene's concentration. Centene has 8.74 million standalone PDP members and 0.92 million MA-PD members, resulting in a standalone share of 90% and a PDP-to-MA-PD ratio of 9.5x. In comparison, CVS Health has 3.86 million standalone and 3.17 million MA-PD members (55% standalone, 1.2x ratio), Humana has 3.68 million standalone and 6.21 million MA-PD members (37% standalone, 0.6x), and UnitedHealth has 3.74 million standalone and 8.03 million MA-PD members (32% standalone, 0.5x).
The scale of Centene's exposure is further underscored by its Wellcare Value Script plan, which serves 6.1 million individuals outside group coverage. The plan's typical monthly premium is under $6, and enrollment grew by 1.1 million for 2026. At this scale, even minor shifts in retention can have significant financial impacts. Wellcare Value Script accounts for approximately one-third of the non-group standalone market, and maintaining its low-price strategy could become challenging if the subsidy is removed.
Premium Increases and Policy Comparisons
CMS has released initial technical figures for 2027, indicating a 23.7% increase in the national average monthly bid, from $239.27 in 2026 to $296.05 in 2027. This bid figure is used to calculate government subsidies and does not represent an estimate of consumer premiums. The base beneficiary premium will increase by the statutory maximum of 6%, from $38.99 to $41.33. The demonstration premium reduction of $10 per month will end, and the premium-increase limit of $50 per month will also be withdrawn. The annual drug out-of-pocket cap is projected to rise by 14.3%, from $2,100 to $2,400.
The average standalone premium for 2027 is yet to be announced, with expectations set for September. CMS Administrator Mehmet Oz has stated that the majority of beneficiaries could expect monthly increases of less than $10. However, Nancy LeaMond, executive vice president at AARP, remarked that it was “too early to know the full impact.”
Standalone PDP vs. Medicare Advantage
The premium disparity between standalone PDPs and Medicare Advantage drug plans (MA-PDs) is a key factor. In 2026, the average monthly drug premium for standalone PDPs is $36, compared to just $8 for MA-PDs. Moreover, only 28% of non-subsidized members in standalone plans have zero-premium plans, whereas 79% of MA-PD members do. Medicare Advantage providers can apply rebate dollars to reduce drug premiums, an option not available to standalone plan sponsors. This structural advantage makes MA-PDs more attractive to beneficiaries, potentially accelerating migration away from standalone plans.
Humana's recent earnings highlight the importance of this hedge. The company's individual Medicare Advantage enrollment increased by 23% in the quarter, and CEO Jim Rechtin stated that this growth would “further fuel” the company's earnings potential. Humana reaffirmed its adjusted earnings outlook for 2026 at a minimum of $9 per share.
Market Reactions and Risks
During Friday's afternoon session, insurer stocks showed mixed movements. Centene was up 1.7% at $61.88, Humana rose 0.2% to $367.56, CVS Health gained 0.2% to $105.46, and UnitedHealth slipped 0.5% to $419.49. These moves do not reflect a broad policy-driven sector selloff, as insurers also reacted to earnings announcements over the week. Centene's larger gain came after recent swings tied to Medicaid outlook concerns.
Looking ahead, risks include the possibility that September premiums might increase by less than anticipated, which could mitigate churn. Beneficiaries may also choose other standalone plans instead of moving into Medicare Advantage, and employer-group participants often do not have control over these decisions. However, migration to Medicare Advantage can raise medical-cost risks for insurers. Centene forecasts an 8% to 9% drop in Medicaid membership for the year, adding to its challenges. As the subsidy phaseout approaches, insurers must navigate these uncertainties to maintain their competitive positions.
